Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.65 |
| ▸ | MAOA | P21397 | 2/20 | 0.65 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.63 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.63 |
| ▸ | CXCL12 | P48061 | 2/20 | 0.62 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL498894 | 1.00 | MAOB (0.65) | MAOBMAOAALOX5PTGS1PTGS2 | |
| SCHEMBL13359041 | 0.87 | MAPT (0.66) | MAOBMAOACYP1B1 | |
| SCHEMBL29151961 | 0.86 | TTR (0.59) | — | |
| SCHEMBL29151956 | 0.86 | TTR (0.59) | — | |
| SCHEMBL3970019 | 0.85 | PTGS1 (0.65) | PTGS1PTGS2CXCL12 | |
| SCHEMBL3970018 | 0.85 | PTGS1 (0.65) | PTGS1PTGS2CXCL12 | |
| SCHEMBL3970919 | 0.84 | TNFRSF1A (0.65) | ALOX5PTGS1PTGS2 | |
| SCHEMBL498633 | 0.84 | ESR1 (0.62) | CYP1B1 | |
| SCHEMBL498634 | 0.84 | ESR1 (0.62) | CYP1B1 | |
| SCHEMBL3974902 | 0.84 | CYP1A2 (0.57) | CXCL12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571843-B1 | IMPROVED PREPARATION OF CHALCONE DERIVATIVES | GENFIT (FR) | 2017-12-27 | — | — | EP | disclosed |
| US-8765992-B2 | Preparation of chalcone derivatives | GENFIT (FR) | 2014-07-01 | — | — | US | disclosed |
| US-8461212-B2 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | GENFIT (FR) | 2013-06-11 | — | — | US | disclosed |
| US-20130131372-A1 | PREPARATION OF CHALCONE DERIVATIVES | GENFIT (FR) | 2013-05-23 | — | — | US | disclosed |
| EP-2571843-A1 | IMPROVED PREPARATION OF CHALCONE DERIVATIVES | Genfit (FR) | 2013-03-27 | — | — | EP | disclosed |
| US-20120129932-A1 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | GENFIT (FR) | 2012-05-24 | — | — | US | disclosed |
| US-8106097-B2 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | GENFIT (FR) | 2012-01-31 | — | — | US | disclosed |
| WO-2011144579-A1 | IMPROVED PREPARATION OF CHALCONE DERIVATIVES | GENFIT (FR) | 2011-11-24 | — | — | WO | disclosed |
| US-8058308-B2 | Substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | GENFIT (FR) | 2011-11-15 | — | — | US | disclosed |
| US-20110190515-A1 | SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | GENFIT (FR) | 2011-08-04 | — | — | US | disclosed |
| US-20070032543-A1 | Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2007-02-08 | — | — | US | disclosed |
| US-20060142611-A1 | Preparation of 1,3-diphenylprop-2-en-1-one derivatives | GENFIT (FR) | 2006-06-29 | — | — | US | disclosed |
| EP-1644312-A1 | PREPARATION OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES | Genfit (FR) | 2006-04-12 | — | — | EP | disclosed |
| US-20050176808-A1 | Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof | GENFIT (FR) | 2005-08-11 | — | — | US | disclosed |
| US-20050171149-A1 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | GENFIT (FR) | 2005-08-04 | — | — | US | disclosed |
| EP-1525177-A1 | SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES AND PREPARATION AND USES THEREOF | Genfit (FR) | 2005-04-27 | — | — | EP | disclosed |
| EP-1519908-A2 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | Genfit (FR) | 2005-04-06 | — | — | EP | disclosed |
| WO-2005005369-A1 | PREPARATION OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES | GENFIT (FR) | 2005-01-20 | — | — | WO | disclosed |
| WO-2004005243-A2 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES | GENFIT (FR) | 2004-01-15 | — | — | WO | disclosed |
| WO-2004005233-A1 | SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES AND PREPARATION AND USES THEREOF | GENFIT (FR) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032543-A1 | Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients | PSEN1, BACE1, PSEN2 | MAOB 2058/4885MAOA 1731/4885ALOX5 479/4885 |
| US-20110190515-A1 | SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | PGF, PTGS1, PTGES3 | MAOB 705/4885MAOA 953/4885ALOX5 542/4885 |
| US-20120129932-A1 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | BRCA1, COL1A1, APOL1 | MAOB 840/4885MAOA 207/4885ALOX5 48/4885 |
| US-20050176808-A1 | Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof | PGF, PTGS1, PTGES3 | MAOB 692/4885MAOA 952/4885ALOX5 564/4885 |
| US-20050171149-A1 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | BRCA1, LOXL1, APOL1 | MAOB 845/4885MAOA 260/4885ALOX5 23/4885 |
| US-20060142611-A1 | Preparation of 1,3-diphenylprop-2-en-1-one derivatives | DPEP1, PKD1, ENPP1 | MAOB 2735/4885MAOA 3068/4885ALOX5 389/4885 |
| US-20130131372-A1 | PREPARATION OF CHALCONE DERIVATIVES | SULT1E1, HCCS, STS | MAOB 1072/4885MAOA 1584/4885ALOX5 1578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.